- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01378624
Ex Vivo Effect of Surfactant Protein D on Pulmonary Cells in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging
Ex Vivo Effect of Fragments and Modified Forms of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The effect of surfactant protein D under native and altered conditions will be investigated in immune cells that are derived from bronchoalveolar lavage in patients with allergic asthma following segmental allergen challenge. The goal of this study is to elucidate the pro- versus anti-inflammatory function of SP-D molecules and to identify motifs of SP-D that have treatment potential in allergic asthma and to assess local inflammation induced by segmental allergen challenge by magnetic resonance imaging.
In addition to the patients with allergic asthma a subgroup of five healthy subjects will be included into the study to elucidate the specificity of the SP-D (surfactant protein-D) effect on the allergic inflammation in the invitro models.
The primary objective of this study is to isolate BAL cells for different invitro experiments and to assess local inflammation after segmental allergen challenge by MRI in response to the applied allergen dose.
Therefore, following a baseline BAL, allergen (2× individual dose, 1× one tenth of individual dose) and saline (1×) will be instilled into four different lung segments during a first bronchoscopy. After 24 hours during a second bronchoscopy BAL will be collected in these challenged segments to harvest invaded cells for invitro experimentation. In addition, bronchial biopsies and epithelial brushes will be taken to assess the degree of local inflammation in bronchial mucosa and to study the activation of airway epithelium following allergen challenge.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30625
- Fraunhofer ITEM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able and willing to give written informed consent
- Physician diagnosis of mild asthma according to GINA guidelines (1;7)
- Nonsmokers with a history of less than 1 pack a year having been nonsmokers for at least the last five years
- FEV1 80% of predicted
- Positive skin prick test for grass mix or D. pteronyssinus at or within 12 months prior to the screening visit
- Positive response to an incremental inhaled allergen challenge with house dust mite allergen or grass pollen allergen
Women will be considered for inclusion if they are:
- Not pregnant, as confirmed by pregnancy test, and not nursing
- Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit)o of childbearing potential and using a highly effective method of contraception during the entire study (vasectomized partner, sexual abstinence
- The lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the study until at least 72 hours after the end of the study
- Implants, injectables, combined oral contraceptives, hormonal IUDs, or double barrier methods (i.e. any double combination of IUD, condom with spermicidal gel,diaphragm, sponge, and cervical cap)
Exclusion Criteria:
- History of upper or lower respiratory tract infection four weeks prior to the informed consent visit
- Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, psychiatric disease, endocrine disease, infectious disease, inflammatory disease, or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
- Clinically significant pathological findings in safety laboratory tests
- Regular intake of any medication other than short acting inhaled beta agonists, paracetamol for pain relief, birth control medication, hormonal replacement therapy, dietary and vitamin supplements
- Specific Immunotherapy (SIT) within two years prior to the study
- Use of anti-inflammatory medication including systemic or inhaled corticosteroid within the last four weeks
- Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures.
- Suspected hypersensitivity to any ingredients of the medication in line with bronchoscopy (bronchodilators, sedatives and local anesthetics)
- Conditions or factors, which would make the subject unlikely to be able to undergo bronchoscopy or incremental allergen challenge
- Conditions or factors, which would make the subject unable to undergo MRI such as metal containing implants, remainders of shell splinters or bullets, or claustrophobia.
- History of drug or alcohol abuse
- Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.
- Participation in a clinical trial 30 days prior to enrollment
- Segmental allergen challenge three months prior to treatment
- Risk of non-compliance with study procedures
- Calculated GFR <30 ml/min/1.73 m2
- Known allergy to MRI based contrast agents
- Donation of more than 500 ml of blood in the preceding 9 weeks before the trial examination
- Hb Hemoglobin below lower limit of normal value
Additional Inclusion Criteria for healthy control subjects:
- Healthy subjects with no clinical evidence of allergic rhinitis and respiratory disease (e.g. asthma)
- Negative skin prick test for grass mix or D. pteronyssinus at or within 12 months prior to the screening visit
- Negative response to an incremental metacholine challenge (PC20 ≥ 8mg/ml)
- Total IgE (Immunglobulin E) <100 IU/ml
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bronchoscopy
|
In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled. The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in local inflammation
Time Frame: Baseline, 6 and 24 hours post segmental allergen challenge
|
Magnetic resonance imaging to assess local inflammation prior to as well as 6 h and 24 h after segmental allergen challenge
|
Baseline, 6 and 24 hours post segmental allergen challenge
|
Change of numbers of matured dendritic cells
Time Frame: Baseline and 24 h post segmental allergen challenge
|
Change of numbers of matured dendritic cells in vitro in the absence and presence of surfactant protein D.
|
Baseline and 24 h post segmental allergen challenge
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jens Hohlfeld, MD, Professor, Fraunhofer ITEM
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-07 ZAP2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Intermittent Asthma (Gina 1)
-
Fraunhofer-Institute of Toxicology and Experimental...Institute for Pharmacology and Toxicology, RWTH AachenCompletedHealthy Volunteers | COPD GOLD I to IV | Asthma GINA 1 to 4Germany
-
Hamilton Health Sciences CorporationAstraZenecaCompletedMild Intermittent AsthmaCanada
-
Laboratorios Leti, S.L.Harrison Clinical ResearchTerminatedAllergic Rhinitis | Mild Persistent Asthma | Rhinoconjunctivitis | Mild Intermittent AsthmaSpain
-
Queen Mary University of LondonUniversity of Nottingham; University of Edinburgh; University of Cambridge; National... and other collaboratorsRecruitingAsthma Intermittent, UncontrolledUnited Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedMild Persistent AsthmaUnited Kingdom
-
Societa Italiana di PneumologiaSocietà Italiana di Allergologia, Asma e Immunologia ClinicaRecruiting
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH)TerminatedMild Allergic Rhinitis | Mild Allergic Rhinitis With Mild AsthmaUnited States
-
SamA Pharmaceutical Co., LtdCompleted
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS); Purdue UniversityCompletedMild, Allergic AsthmaUnited States
-
Intech Biopharm Ltd.Recruiting
Clinical Trials on Bronchoscopy
-
Ankara Ataturk Sanatorium Training and Research...Yenimahalle Education and Research HospitalCompletedIntensive Care Unit | Tracheal StenosisTurkey
-
Tang-Du HospitalChanghai Hospital; The First Affiliated Hospital of Guangzhou Medical University and other collaboratorsTerminated
-
Jiayuan SunUnknown
-
Wake Forest University Health SciencesOhio State University; University of Mississippi Medical CenterCompletedBone Marrow TransplantationUnited States
-
Charite University, Berlin, GermanyUniversity of Luebeck; NeuroCure Clinical Research Center, Charite, Berlin; University... and other collaboratorsRecruiting
-
Centre Hospitalier Universitaire de NiceCompleted
-
University of VirginiaCompleted
-
University Medical Center GroningenUnknownAsthma | Allergic AsthmaNetherlands
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Instituto de Salud Carlos...UnknownBacterial Infection in COPDSpain